Rituximab as First-Line Treatment of Patients With Follicular

News
Article
OncologyONCOLOGY Vol 14 No 3
Volume 14
Issue 3

There is no standard treatment of stage III-IV follicular lymphoma patients with a low-tumor burden. Rituximab (Rituxan), a chimeric anti-CD20 antibody, is active in pretreated patients with an overall response (OR) rate of 50% and good tolerance.

There is no standard treatment of stage III-IV follicular lymphoma patients with a low-tumor burden. Rituximab (Rituxan), a chimeric anti-CD20 antibody, is active in pretreated patients with an overall response (OR) rate of 50% and good tolerance.

We treated patients with good-prognosis follicular lymphoma with the following goals: (1) to evaluate the clinical and molecular efficacy of rituximab in previously untreated patients; and (2) to follow patients in complete molecular remission so as to establish relationships between clinical response and molecular remission. Criteria for inclusion after consent were: a diagnosis of follicular lymphoma (pathology review); age between 18 to 75 years; stage II-IV disease; performance status (PS) 0-1, measurable disease, and the absence of the following criteria: B symptoms, tumor mass > 7 cm, compression, increased serum lactate dehydrogenase (LDH) or beta-2-microglobulin.

Patients were treated with four weekly infusions of rituximab at a dose of 375 mg/m². Polymerase chain reaction (PCR) assays for bcl-2-JH rearrangement (MBR and mcr primers) on blood and bone marrow were performed before treatment and 1, 6, and 12 months after treatment. Among 50 patients included, 52% were males, 92% were PS = 0, 92% were stage III-IV, and 66% had marrow involvement.

The OR rate was 69% with 31% complete responses (CR), 10% unconfirmed CR, and 28% partial responses (PR), according to the criteria of Cheson and coworkers. After a median follow-up of 13 months, 22% of patients have progressed (9% of responders). Of 32 patients who were PCR positive before treatment, 17 (57%) became negative after treatment with rituximab. Of the latter patients, 12 were analyzed after 12 months, and 10 remained PCR negative. Molecular remission was strongly associated with clinical response and absence of progression. Only two transient grade 3 infusion-related toxicities were observed.

CONCLUSION: Rituximab has high efficacy and low toxicity in previously untreated patients with low–tumor burden follicular lymphoma. In addition, it induces complete molecular remission in > 50% of evaluable patients and, thus, may represent a curative approach.

Click here for Dr. Bruce Cheson’s commentary on this abstract.

Articles in this issue

Comparative Economic Analysis of the Treatment of Relapsed Low-Grade B-Cell Non-Hodgkin’s Lymphoma (NHL) in France Using CHOP, Fludarabine, or Rituximab
FHIT Gene, Smoking, and Cervical Cancer
Final Report on the Safety and Efficacy of Retreatment With Rituximab for Patients With Non-Hodgkins Lymphoma
Prospective, Randomized, Controlled Study of Zevalin Radioimmunotherapy Compared to Rituximab Immunotherapy for B-Cell, Non-Hodgkins Lymphoma: Interim Results
IOM Medical Error Estimates Questioned, But Legislation Considered
Less Toxic Therapies for Hodgkin’s Disease May Reduce Secondary Cancers
Preserving Fertility in Young Women With Ovarian Cancer Does Not Decrease Survival
Iodine-131 Tositumomab for Patients With Transformed, Low-Grade Non-Hodgkin’s Lymphoma: Overall Clinical Trial Experience
Survival Rates Significantly Worse For African-Americans With Endometrial Cancer
Rituximab Has Significant Activity in Patients With Chronic Lymphocytic Leukemia
Responders to Rituximab Show Continued Tumor Regression Over Time and a Progression-Free Survival That Correlates With Response Classification
PhRMA Criticizes FDA’s Proposed Rule on Antibiotic Approvals
Phase II Study of Rituximab in Combination With CHOP in Patients With Previously Untreated Intermediate- or High-Grade Non-Hodgkin’s Lymphoma
New Antibiotic Effective in Treating Gram-Positive Bacteremia
Reduced-Dose Zevalin Radioimmunotherapy for Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma Patients With Preexisting Thrombocytopenia: Report of Interim Results of a Phase II Trial
Related Videos
The approval for epcoritamab in patients with R/R follicular lymphoma was supported by encouraging efficacy findings from the phase 1/2 EPCORE NHL-1 trial.
This series features 2 KOLs.
This series features 2 KOLs.
relapsed or refractory mantle cell lymphoma, glofitamab, Obinutuzumab, phase 1/2 study, NCT03075696, Tycel J. Phillips, MD
This series features 2 KOLs.
This series features 2 KOLs.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
There is no absolute age cutoff where CAR T cells are contraindicated for those with large B-cell lymphoma, says David L. Porter, MD.
Related Content